{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T15:38:14Z","timestamp":1783352294266,"version":"3.54.6"},"reference-count":35,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Clin Microbiol"],"published-print":{"date-parts":[[2025,2,19]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:sec>\n            <jats:title\/>\n            <jats:p>\n              This study addresses the use of other echinocandins as surrogate markers to predict the susceptibility of rezafungin against the six most common\n              <jats:italic>Candida<\/jats:italic>\n              spp. The Clinical Laboratory Standards Institute (CLSI) reference broth microdilution method was performed to test 5,720 clinical isolates of six different\n              <jats:italic>Candida<\/jats:italic>\n              species. Species-specific interpretative criteria by CLSI breakpoints or epidemiological cutoff values were applied. Essential agreement was 100% within two doubling dilutions for all species and comparisons. The categorical agreement of rezafungin using anidulafungin against all\n              <jats:italic>Candida<\/jats:italic>\n              spp. was 97.6% (2.9% very major errors [VMEs], 0.2% major errors [MEs], and 2.2% minor errors [miEs]); for caspofungin, it was 99.6% (11.4% VME, 0.09% ME, and 0.19% miE); and for micafungin, it was 99.6% (14.3% VME, 0.15% ME, and 0.17% miE). There were species-specific differences that led to unacceptably high VME for\n              <jats:italic>Candida dubliniensis<\/jats:italic>\n              with all agents and for\n              <jats:italic>Candida parapsilosis<\/jats:italic>\n              when caspofungin or micafungin but not anidulafungin was used as the comparator. Genetic analysis showed rezafungin nonsusceptibility correlated well with FKS hotspot mutations. The best-performing surrogate was anidulafungin, which can be used to predict rezafungin susceptible or nonsusceptible in\n              <jats:italic>Candida albicans, Candida glabrata, Candida parapsilosis, Candida tropicalis,<\/jats:italic>\n              and\n              <jats:italic>Candida krusei<\/jats:italic>\n              with low error rates and \u226590% essential and categorical agreement. Micafungin or caspofungin can also be used as a surrogate marker for predicting rezafungin susceptible or nonsusceptible in\n              <jats:italic>C. albicans<\/jats:italic>\n              ,\n              <jats:italic>C. glabrata<\/jats:italic>\n              ,\n              <jats:italic>C. tropicalis<\/jats:italic>\n              , and\n              <jats:italic>C. krusei<\/jats:italic>\n              . No surrogate performs appropriately to determine rezafungin susceptibility for\n              <jats:italic>C. dubliniensis<\/jats:italic>\n              .\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1128\/jcm.01129-24","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T14:00:44Z","timestamp":1737554444000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":4,"title":["Anidulafungin is a useful surrogate marker for predicting\n            <i>in vitro<\/i>\n            susceptibility to rezafungin among five\n            <i>Candida<\/i>\n            species using CLSI methods and interpretive criteria"],"prefix":"10.1128","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9785-5034","authenticated-orcid":true,"given":"Marisa L.","family":"Winkler","sequence":"first","affiliation":[{"name":"Element Iowa City (JMI Laboratories)","place":["North Liberty, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1709-1132","authenticated-orcid":true,"given":"Lalitagauri","family":"Deshpande","sequence":"additional","affiliation":[{"name":"Element Iowa City (JMI Laboratories)","place":["North Liberty, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0457-1543","authenticated-orcid":true,"given":"John H.","family":"Kimbrough","sequence":"additional","affiliation":[{"name":"Element Iowa City (JMI Laboratories)","place":["North Liberty, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maura","family":"Karr","sequence":"additional","affiliation":[{"name":"Element Iowa City (JMI Laboratories)","place":["North Liberty, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Rhomberg","sequence":"additional","affiliation":[{"name":"Element Iowa City (JMI Laboratories)","place":["North Liberty, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abby L.","family":"Klauer","sequence":"additional","affiliation":[{"name":"Element Iowa City (JMI Laboratories)","place":["North Liberty, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0126-1782","authenticated-orcid":true,"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[{"name":"Element Iowa City (JMI Laboratories)","place":["North Liberty, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.02449-21"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00099-20"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01556-19"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00701-16"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2018.02.013"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02603-17"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01627-16"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/cmi.12640"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00551-0"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1380"},{"key":"e_1_3_4_12_2","unstructured":"Therapeutics M. 2023. REZZAYO (rezafungin for injection) for intravenous use [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/217417s000lbl.pdf."},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02324-8"},{"key":"e_1_3_4_14_2","unstructured":"Scientific TF. 2024. Sensititre YeastOne YO4IVD. Available from: https:\/\/www.thermofisher.com\/document-connect\/document-connect.html?url=https:\/\/assets.thermofisher.com\/TFS-Assets%2FMBD%2Fbrochures%2FSensititre-YeastOne-Plates-Product-Overview-EN.pdf. Retrieved 19 Jul 2024."},{"key":"e_1_3_4_15_2","volume-title":"M27 M44S Ed3. Performance standards for antifungal susceptibility testing of yeasts","author":"CLSI","year":"2022","unstructured":"CLSI. 2022. M27 M44S Ed3. Performance standards for antifungal susceptibility testing of yeasts. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkad055"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ933"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw691"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.ss6808a1"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit136"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.8.3264-3273.2005"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01711-09"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00349-06"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2007.04.002"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00473-08"},{"key":"e_1_3_4_26_2","volume-title":"M27 Ed4. Reference method for broth dilution antifungal susceptibility testing of yeasts","author":"CLSI","year":"2017","unstructured":"CLSI. 2017. M27 Ed4. Reference method for broth dilution antifungal susceptibility testing of yeasts. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_4_27_2","volume-title":"M57S Ed4. Epidemiological cutoff values for antifungal susceptibility testing","author":"CLSI","year":"2022","unstructured":"CLSI. 2022. M57S Ed4. Epidemiological cutoff values for antifungal susceptibility testing. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00782-14"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01934-17"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.06112-11"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01674-13"},{"key":"e_1_3_4_32_2","volume-title":"M60 Ed2 performance standards for antifungal susceptibility testing of yeasts","author":"CLSI","year":"2020","unstructured":"CLSI. 2020. M60 Ed2 performance standards for antifungal susceptibility testing of yeasts. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_4_33_2","volume-title":"M52 Ed1. Verification of commercial microbial identification and antimicrobial susceptibility testing systems","author":"CLSI","year":"2015","unstructured":"CLSI. 2015. M52 Ed1. Verification of commercial microbial identification and antimicrobial susceptibility testing systems. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01519-13"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.03593-13"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00262-08"}],"container-title":["Journal of Clinical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/jcm.01129-24","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/jcm.01129-24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T05:10:51Z","timestamp":1743743451000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/jcm.01129-24"}},"subtitle":[],"editor":[{"given":"Kimberly E.","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2,19]]}},"alternative-id":["10.1128\/jcm.01129-24"],"URL":"https:\/\/doi.org\/10.1128\/jcm.01129-24","relation":{},"ISSN":["0095-1137","1098-660X"],"issn-type":[{"value":"0095-1137","type":"print"},{"value":"1098-660X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,19]]},"assertion":[{"value":"2024-07-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01129-24"}}